Skip to main content
IOVA
NASDAQ Life Sciences

Iovance Posts Record $122M Q3 Revenue, 60% Gross Margin; Reiterates $410-420M FY Guidance

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9.24
Mkt Cap
$3.941B
52W Low
$1.76
52W High
$15.37
52W Position info
425% above low
Off High info
40% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IOVA has more than doubled off its 52-week low of $1.76.

Summary

Iovance reported record Q3 2026 product revenue of about $122 million, up roughly 80% year-over-year from $67 million and 22% sequentially from $99 million. U.S. Amtagvi sales drove the quarter at about $102 million, with global Proleukin adding about $20 million. Gross margin climbed to about 60% from 56% in Q2, and R&D spending fell about 16% sequentially, the fifth straight quarter of improvement. Net loss narrowed to $22.3 million, or $0.05 per share, from $91.3 million a year ago, and operating income was USD -23.968 million versus an IBES estimate of USD -40.8 million. Management reiterated full-year 2026 revenue guidance of $410-$420 million, the same range raised on September 29th, and said cash of about $382 million funds operations into 2029. The quarter confirms the commercial ramp is holding after the September guidance hike; the next hard data points are the UK and Swiss Amtagvi approval decisions expected in the first quarter of 2027.

At the time of this announcement, IOVA was trading at $9.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $1.76 to $15.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

IOVA - Latest Insights

IOVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.43
Real-time Price: $7.30 info
Change: -$1.13 (-13%) info
Market Cap: $3.382B info
IOVA
Oct 29, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $7.30 info
Change: -$2.08 (-22%) info
Market Cap: $3.382B info
IOVA
Oct 29, 2026, 3:11 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $9.69
Real-time Price: $7.30 info
Change: -$2.39 (-25%) info
Market Cap: $3.382B info
IOVA
Oct 29, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.13
Real-time Price: $7.30 info
Change: -$5.83 (-44%) info
Market Cap: $3.382B info
IOVA
Oct 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.30
Real-time Price: $7.30 info
Change: -$7.00 (-49%) info
Market Cap: $3.382B info